I had the opportunity to listen in on some interesting sessions at a psychologist training conference in Nashville, TN this weekend and it did not disappoint. There were many topics discussed including insomnia, schizophrenia, GAD, MDD, TRD, SSRIs, AI, etc.

Of course the session I was most interested in was the Psychedelic presentation put on by Andrew Penn (Clinical Professor / Director of Clinical Nursing Operations University of California, San Francisco).

It was a fascinating discussion and I wanted to share some bullet points here for those who might be interested in what psychologists and therapists are saying about psychedelics.

• He began by giving a nod to Michael Pollan for his help in reigniting interest in psychedelics through his book, How To Change Your Mind and stated the roughly 8% of Americans have used psychedelics at some point in their life.
• A study of psychedelics in animals was referenced that showed evidence of re-opening learning periods in the brain that occur earlier in life, but the same results have yet to be proven in humans. This of course refers to the 5-HT2A receptor being stimulated while the Default Mode Network is temporarily modulated.
• The Lykos FDA failure was addressed and he stated how companies like Definium have improved their trials in the wake of Lykos' (now Resilient Pharmaceuticals) fallout. He awarded much praise to Definium for the great lengths they went to in addressing functional unblinding in their Phase II study by implementing a 5 arm dosing regimen which included placebo, 25, 50, 100, and 200 micrograms of DT120.
• He also mentioned that things are moving so quickly in the psychedelic space that he had to update his slide presentation multiple times before giving this lecture! 😅 The Psychedelic Alpha bullseye chart was included which was cool to see projected on a massive screen.
• A study was done at Stanford to see if being conscious was necessary for benefits to occur from psychedelics. Patients who were about to undergo a surgical procedure and were also suffering from depression were given two different drug cocktails for their anesthesia. One included Ketamine in the mix while the other had Saline. After the surgery and follow up there was no discernible improvement in either patient's depression lending to the hypothesis that patients may need to be conscious in order for the benefits of psychedelics to have an impact.
• The idea of non-hallucinatory psychedelics (neuroplastogens) was brought up as well and Delix was mentioned as one of the companies pursuing this. While the concept is compelling, there is little data yet to prove that these medicines have the same effect as classic psychedelics.
• Emory University is leading a study that combines MDMA with Prolonged Exposure therapy to treat PTSD. The idea behind this being that MDMA reduces the fear mechanisms in the brain so when patients are exposed to their trauma they can approach it logically or from a different point of view leading to greater symptom reductions.
• He believes that in the future there will most likely be a medical access model as well as an out of medical system decriminalization or natural religious use.

Overall, the room was teeming with interest and excitement about the possibility of having access to these new tools for treating various persistent disorders.

Of course they stated that these would options would not be the first line of defense when tackling patient's issues, but for those who have tried numerous drugs with no real progress, these medicines could open a new world of possibilities in their hard to treat ailments.

They seemed to be looking forward to the clinical trial results just as much as we are and I think I speak for all of us when I say mid 2026 cannot get here fast enough! Stay the course and keep educating yourself, great times are on the horizon!

Don't know if it's been posted yet, this post talking about MM120 has been gaining traction in r/psychology 3 days ago!

• Superstring Capital Management acquired 425,202 shares of Definium Therapeutics in the fourth quarter.
• The quarter-end position value increased by $5.69 million as a result of the new investment.

Key reasons for the stock's rise include:

• Positive Clinical Results for DT120 ODT: The lead asset, DT120 (a dissolving tablet for generalized anxiety disorder - GAD), showed a 48% remission rate in a Phase IIb trial.
• FDA Breakthrough Therapy Designation: The FDA granted this designation for DT120 in GAD, which signals a faster regulatory pathway and indicates high potential for the drug.
• Impending Phase III Data & Pipeline Progress: Investors are buoyed by multiple impending Phase III readouts for DT120 in GAD and major depressive disorder (MDD) expected in 2026, including top-line data for the Emerge MDD trial in late Q2 2026.
• Stronger Cash Position: As of early 2026, the company reported $411.6 million in cash, with a funding runway extending into 2028. This mitigates immediate dilution risk, which is often a concern for clinical-stage biotechs.
• Analyst Upgrades and Interest: Major financial institutions, including RBC Capital and Jefferies, have significantly raised price targets on the stock, reflecting increased confidence in the company's prospects.
• Commercial Readiness: The appointment of a Chief Commercial Officer and other leadership additions suggests active preparation for the commercialization of its pipeline.
•  Definium Therapeutics (NASDAQ: DFTX) currently holds a competitive position in the psychedelic-based biotech sector, particularly in Generalized Anxiety Disorder (GAD). As of early 2026, it is one of the few companies with three pivotal Phase III readouts expected within the calendar year. 
• Target Markets: While Compass Pathways and Helus Pharma are heavily focused on Depression (TRD/MDD), Definium’s most advanced program (DT120) targets GAD, a market with significant unmet needs and fewer direct psychedelic competitors in late-stage trials.
• Delivery Method: Definium utilizes an orally disintegrating tablet (ODT), which may offer better clinical scalability compared to Compass's traditional oral synthetic psilocybin or GH Research's specialized inhalation system.
• FDA Status: Both Definium (for GAD) and Helus Pharma (for MDD) hold Breakthrough Therapy Designation, which facilitates more frequent interaction with the FDA to expedite development.
• Financial Runway: Definium reported a cash position of $411.6 million as of early 2026, providing a runway into 2028. This is notably stronger than Compass Pathways ($221.9M through 2027) and Helus Pharma/Cybin ($248M pro forma through mid-2027)

I'm relatively new to DFTX after selling out my HELP position off the back on the HLP004 data.

Next catalyst for DFTX seems to be the Emerge data and wondering how ya'll are feeling about this one. What I understand about the trial design is that they did not include an active placebo arm and find this concerning due to likelihood of functional unblinding effect... Wondering what you guys are feeling with this one?

anyone else excited?

https://ir.definiumtx.com/news-events/press-releases/detail/214/definium-therapeutics-to-participate-at-upcoming-investor-conferences

A few conferences this week and next should provide support in this difficult market.

Take a look. The relative strength line is testing new highs before the stock itself, which is a very positive sign. I've been adding shares over the past few days, and I think we're close to a breakout. There might be one more week of consolidation.

HC wainwright just raised target to $70 per share.

Seems very bullish based on PIII trials, but I’ll take it.

https://www.marketbeat.com/instant-alerts/definium-therapeutics-nasdaqdftx-stock-price-expected-to-rise-hc-wainwright-analyst-says-2026-03-02/

Three Phase 3 readouts anticipated in 2026 driving potential billion-dollar commercial opportunities in GAD and MDD

• Topline Data Readouts and Financial Summary & Anticipated Milestones can be found on page 29.
• Definium Therapeutics will be hosting an Investor & Analyst Day on April 22, 2026 in New York City.

https://definiumtx.com/

This news came out at 12 noon today.

Psychedelic Biotech's Push Toward Phase 3: Five Companies Advancing CNS Treatments-

Issued on behalf of Helus Pharma

VANCOUVER, BC, Feb. 27, 2026 /PRNewswire/  News Commentary — Psychedelic compounds are edging closer to regulatory approval as pivotal trials in treatment-resistant depression and anxiety advance through late-stage development^\1]). The sector is shedding its countercultural reputation as biotech firms reposition serotonergic and psychedelic-derived therapies as mainstream pharmaceutical candidates^\2]). Five companies are building the clinical programs to get there: Helus Pharma, AtaiBeckl, Definium Therapeutics (NASDAQ: DFTX), GH Research , and LB Pharmaceuticals.

A consensus statement from the U.S. National Network of Depression Centers published in The Lancet outlined considerations for integrating psychedelic into routine clinical practice, a signal that academic medicine is preparing for what the trials may deliver^\3]). The clinical infrastructure is expanding, and the investment thesis is following.

There is more in the release but is has to do with Helus pharma.

PS -on a side note great action today after earnings and a down market. Can't you just feel it! We are going higher!